Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06864793
QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06852456
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
Phase 3
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: QLG1080
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT06837896
Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Tumor
- Interventions
- Drug: QLS1304 tablet
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06823609
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
Phase 3
Not yet recruiting
- Conditions
- Schizophrenia
- Interventions
- Drug: 3-6mg QLM1016Drug: 10-20 mg Aripiprazole oral solution film
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06799559
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
Phase 3
Not yet recruiting
- Conditions
- Small-cell Lung Cancer
- Interventions
- Drug: Iparomlimab and Tuvonralimab (QL1706)Drug: placebo for QL1604Drug: placebo for Iparomlimab and Tuvonralimab (QL1706)
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 636
- Registration Number
- NCT06789796
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Phase 3
Not yet recruiting
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 464
- Registration Number
- NCT06754644
Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
Phase 2
Not yet recruiting
- Conditions
- Primary Hypercholesterolemia or Mixed Hyperlipidemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06750341
Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
Phase 3
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: MonosialogangliosideDrug: Placebo
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1232
- Registration Number
- NCT06742216
- Locations
- 🇨🇳
Nanjing Gulou Medical College Affiliated Hospital, Nanjing, China
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Phase 3
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 284
- Registration Number
- NCT06742138
© Copyright 2025. All Rights Reserved by MedPath